These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19319689)

  • 21. Why should we bother? Ethical and social issues in individualized medicine.
    Paul NW; Fangerau H
    Curr Drug Targets; 2006 Dec; 7(12):1721-7. PubMed ID: 17168846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetics and the practice of medicine.
    Roses AD
    Nature; 2000 Jun; 405(6788):857-65. PubMed ID: 10866212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ethical and legal implications of pharmacogenomics.
    Rothstein MA; Epps PG
    Nat Rev Genet; 2001 Mar; 2(3):228-31. PubMed ID: 11256075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Consumers' views of pharmacogenetics--A qualitative study.
    Haddy CA; Ward HM; Angley MT; McKinnon RA
    Res Social Adm Pharm; 2010 Sep; 6(3):221-31. PubMed ID: 20813335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AAPS and US FDA Crystal City VI workshop on bioanalytical method validation for biomarkers.
    Lowes S; Ackermann BL
    Bioanalysis; 2016 Feb; 8(3):163-7. PubMed ID: 26795584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conference Report: High-resolution MS in drug discovery and development: current applications and future perspectives.
    Weston DJ; Weidolf L
    Bioanalysis; 2012 Mar; 4(5):481-6. PubMed ID: 22409547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A look at the future of pediatric therapeutics: an investigator's perspective of the new pediatric rule.
    Connor JD
    Pediatrics; 1999 Sep; 104(3 Pt 2):610-3. PubMed ID: 10469801
    [No Abstract]   [Full Text] [Related]  

  • 28. From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community.
    Frueh FW; Gurwitz D
    Pharmacogenomics; 2004 Jul; 5(5):571-9. PubMed ID: 15212593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The drug diagnostic co-development concept paper: commentary from the 3rd FDA-DIA-PWG-PhRMA-BIO Pharmacogenomics Workshop.
    Hinman LM; Huang SM; Hackett J; Koch WH; Love PY; Pennello G; Torres-Cabassa A; Webster C
    Pharmacogenomics J; 2006; 6(6):375-80. PubMed ID: 16652120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenomics: history, barriers, and regulatory solutions.
    Blankstein S
    Food Drug Law J; 2014; 69(2):273-314, ii. PubMed ID: 25163212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrating pharmacogenomics into pharmacy practice via medication therapy management.
    Reiss SM;
    J Am Pharm Assoc (2003); 2011; 51(6):e64-74. PubMed ID: 22001957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Personalized medicine and rescuing "unsafe" drugs with pharmacogenomics: a regulatory perspective.
    Avery M
    Food Drug Law J; 2010; 65(1):37-65, i-ii. PubMed ID: 24475534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA.
    Lesko LJ; Zineh I
    Pharmacogenomics; 2010 Apr; 11(4):507-12. PubMed ID: 20350131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective.
    Maliepaard M; Nofziger C; Papaluca M; Zineh I; Uyama Y; Prasad K; Grimstein C; Pacanowski M; Ehmann F; Dossena S; Paulmichl M
    Nat Rev Drug Discov; 2013 Feb; 12(2):103-15. PubMed ID: 23370249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unveiling the guidance heterogeneity for genome-informed drug treatment interventions among regulatory bodies and research consortia.
    Koutsilieri S; Tzioufa F; Sismanoglou DC; Patrinos GP
    Pharmacol Res; 2020 Mar; 153():104590. PubMed ID: 31830522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Future of pediatric therapeutics: reauthorization of BPCA and PREA.
    Ward RM; Kauffman R
    Clin Pharmacol Ther; 2007 Apr; 81(4):477-9. PubMed ID: 17375103
    [No Abstract]   [Full Text] [Related]  

  • 37. [Integration of pharmacogenetics in the medical practice].
    Dideberg V; Bours V
    Rev Med Liege; 2005 Dec; 60(12):918-22. PubMed ID: 16457391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assuring quality and performance of sustained and controlled release parenterals: AAPS workshop report, co-sponsored by FDA and USP.
    Burgess DJ; Hussain AS; Ingallinera TS; Chen ML
    Pharm Res; 2002 Nov; 19(11):1761-8. PubMed ID: 12458685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenetics: ethical issues and policy options.
    Buchanan A; Califano A; Kahn J; McPherson E; Robertson J; Brody B
    Kennedy Inst Ethics J; 2002 Mar; 12(1):1-15. PubMed ID: 12211263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic phenotype prediction from genotyping data: a bottleneck for the implementation of pharmacogenetics in drug development and clinical practice.
    LLerena A; Peñas-Lledó EM
    Drug Metab Pers Ther; 2015 Sep; 30(3):143-5. PubMed ID: 26353178
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.